Articles with public access mandates - Naoki NiikuraLearn more
Not available anywhere: 1
Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers
M Kai, T Kogawa, DD Liu, TM Fouad, K Kai, N Niikura, L Hsu, JS Willey, ...
Clinical breast cancer 15 (1), 37-42, 2015
Mandates: US National Institutes of Health
Available somewhere: 15
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ...
New England Journal of Medicine 387 (1), 9-20, 2022
Mandates: US National Institutes of Health
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors
N Niikura, J Liu, N Hayashi, EA Mittendorf, Y Gong, SL Palla, Y Tokuda, ...
Journal of Clinical Oncology 30 (6), 593-599, 2012
Mandates: US National Institutes of Health
FDG‐PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer
N Niikura, CM Costelloe, JE Madewell, N Hayashi, TK Yu, J Liu, SL Palla, ...
The oncologist 16 (8), 1111-1119, 2011
Mandates: US National Institutes of Health
Treatment outcome and prognostic factors for patients with bone‐only metastases of breast cancer: a single‐institution retrospective analysis
N Niikura, J Liu, N Hayashi, SL Palla, Y Tokuda, GN Hortobagyi, NT Ueno, ...
The Oncologist 16 (2), 155-164, 2011
Mandates: US National Institutes of Health
Atezolizumab with neoadjuvant anti–human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer …
J Huober, CH Barrios, N Niikura, M Jarząb, YC Chang, ...
Journal of Clinical Oncology 40 (25), 2946-2956, 2022
Mandates: US National Institutes of Health
Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive …
N Hayashi, N Niikura, H Yamauchi, S Nakamura, NT Ueno
Breast cancer research and treatment 137, 523-531, 2013
Mandates: US National Institutes of Health
A prospective study of bone tumor response assessment in metastatic breast cancer
N Hayashi, CM Costelloe, T Hamaoka, C Wei, N Niikura, RL Theriault, ...
Clinical breast cancer 13 (1), 24-30, 2013
Mandates: US National Institutes of Health
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone‐only metastases
N Niikura, J Liu, N Hayashi, SL Palla, Y Tokuda, GN Hortobagyi, NT Ueno, ...
Cancer 118 (8), 2039-2047, 2012
Mandates: US National Institutes of Health
Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer
N Niikura, J Liu, CM Costelloe, SL Palla, JE Madewell, N Hayashi, TK Yu, ...
The Oncologist 16 (6), 772-782, 2011
Mandates: US National Institutes of Health
Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer
N Hayashi, T Iwamoto, AM Gonzalez-Angulo, J Ferrer-Lozano, A Lluch, ...
The oncologist 16 (7), 956-965, 2011
Mandates: US National Institutes of Health
The role of 18F-FDG-positron emission tomography/computed tomography in staging primary breast cancer
N Niikura, NT Ueno
Journal of Cancer 1, 51, 2010
Mandates: US National Institutes of Health
Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer
N Hayashi, GC Manyam, AM Gonzalez-Angulo, N Niikura, H Yamauchi, ...
The oncologist 19 (9), 909-914, 2014
Mandates: US National Institutes of Health, Susan G. Komen
Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status
N Hayashi, T Iwamoto, Y Qi, N Niikura, L Santarpia, H Yamauchi, ...
Journal of Cancer 8 (6), 1045, 2017
Mandates: US National Institutes of Health
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers
L Vidal, Z Dlamini, S Qian, P Rishi, M Karmo, N Joglekar, S Abedin, ...
ESMO open 9 (5), 103373, 2024
Mandates: National Health and Medical Research Council, Australia
Assessment of the impact of alternative fixatives on HER2 detection in breast Cancer and gastric Cancer tumor specimens
W Feng, R Inoue, T Kuwata, N Niikura, S Fujii, N Kumaki, K Honda, LA Xu, ...
Applied Immunohistochemistry & Molecular Morphology 31 (5), 339-345, 2023
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program